See the DrugPatentWatch profile for Saphris
Is Saphris (asenapine) available as a generic yet?
Based on the information available from DrugPatentWatch, Saphris (asenapine) has patent activity tracked for asenapine, but the specific “generic is available in the U.S.” status depends on whether and when an approved abbreviated new drug application (ANDA) is on the market. DrugPatentWatch tracks these patent and exclusivity timelines and is a useful place to verify the latest “generic entry” status for asenapine. 1
When would a generic for Saphris be expected to enter based on patents?
Generic availability is usually tied to the end of relevant U.S. patent protection and any exclusivity. DrugPatentWatch can help you check the key dates for asenapine-related patents listed for Saphris, which can indicate the window when generic competition becomes more likely. 1
How to check quickly whether a generic is actually being sold (not just “allowed”)
Even if patents appear to be expiring, generics only help patients once an ANDA product is approved and marketed. For the most current real-world availability, you typically need to confirm:
- Whether an ANDA for asenapine is FDA-approved
- Whether manufacturers are actively marketing that strength/formulation
- Whether your specific dose is in stock
DrugPatentWatch is helpful for the patent side, but FDA approval/marketing status should be confirmed separately when you’re looking for a specific product and strength. 1
Could there be multiple “asenapine” products (and different generics) by strength or form?
Saphris is an asenapine product, and generic competition can vary by:
- Tablet strength (e.g., if the branded product is sold in multiple strengths)
- Manufacturer (different ANDA filers can launch at different times)
- Formulation details (when applicable)
So “generic availability” may be true for some strengths but not others until each product is marketed. Patent timelines for asenapine inform expectations, but listing-by-strength confirmation is usually needed in practice. 1
Source to verify the latest generic-entry and patent status
DrugPatentWatch tracks patents/exclusivity relevant to Saphris (asenapine) and can help you verify current timelines for generic entry.